Initiating insulin therapy with, or switching existing insulin therapy to, biphasic insulin aspart 30/70 (NovoMix® 30) in routine care: Safety and effectiveness in patients with type 2 diabetes in the IMPROVE™ observational study

International Journal of Clinical Practice

Volumn 63, Issue 3, 2009, Pages 522-531

  Valensi, P ^a,j   Benroubi, M ^b   Borzi, V ^c   Gumprecht, J ^d   Kawamori, R ^e   Shaban, J ^f   Shah, S ^g   Shestakova, M ^h   Wenying, Y ⁱ  

^a UNIVERSITÉ PARIS 13   (France)

^b KAT HOSPITAL   (Greece)

^c UNIVERSITY OF CATANIA   (Italy)

^d MEDICAL UNIVERSITY OF SILESIA   (Poland)

^e JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f WINDSOR REGIONAL HOSPITAL   (Canada)

^g Bhatia Hospital   (India)

^h N N BLOKHIN NATIONAL MEDICAL RESEARCH CENTER OF ONCOLOGY   (Russian Federation)

ⁱ CHINA JAPAN FRIENDSHIP HOSPITAL   (China)

^j HÔPITAL JEAN VERDIER   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN; INSULIN ASPART;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT CARE; PATIENT SATISFACTION; PRIORITY JOURNAL; QUESTIONNAIRE; SIDE EFFECT; WEIGHT CHANGE;

AGED; DIABETES MELLITUS, TYPE 2; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; PATIENT SATISFACTION; TREATMENT OUTCOME;

EID: 59349100314     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2009.02002.x     Document Type: Article

References (22)

1. International Diabetes Federation. Guideline for Management of Postmeal Glucose. Brussels : International Diabetes Federation, 2007. http://www.idf.org/home/index.cfm?unode=185108C7-1E27-4A03-9B73-01D54087E32E
2. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2008 31 (Suppl. 1 S12 54.
3. Mudaliar S, Edelman SV. Insulin therapy in type 2 diabetes. Endocrinol Metab Clin North Am 2001 30 : 935 82.
4. Nathan DM, Buse JB, Davidson MB et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 2008 31 : 1 11.
5. Brunton S. Insulin regimens for type 2 diabetes mellitus. J Fam Pract 2006 55 : 10S 7S.
6. Ilag LL, Kerr L, Malone JK, Tan MH. Prandial premixed insulin analogue regimens versus basal insulin analogue regimens in the management of type 2 diabetes: an evidence-based comparison. Clin Ther 2007 29 (6P 1254 70.
7. Raskin P, Allen E, Hollander P et al., INITIATE Study Group. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care 2005 28 : 260 5.
8. Kann PH, Wascher T, Zackova V et al. Starting insulin therapy in type 2 diabetes: twice-daily biphasic insulin Aspart 30 plus metformin versus once-daily insulin glargine plus glimepiride. Exp Clin Endocrinol Diabetes 2006 114 : 527 32.
9. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care 2003 26 : 881 5.
10. Jang HC, Guler S, Shestakova M, PRESENT Study Group. When glycaemic targets can no longer be achieved with basal insulin in type 2 diabetes, can simple intensification with a modern premixed insulin help? Results from a subanalysis of the PRESENT study. Int J Clin Pract 2008 62 : 1013 8.
11. Ligthelm RJ, Borzì V, Gumprecht J et al. Importance of observational studies in clinical practice. Clin Ther 2007 29 (6P 1284 92.
12. Liebl A, Prager R, Binz K et al., PREFER Study Group. Comparison of insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER study: a randomized controlled trial. Diabetes Obes Metab 2009 11 : 45 52.
13. Valensi P, Benroubi M, Borzi V et al., on behalf of the IMPROVE™ Study Group Expert Panel. The IMPROVE™ study - a multinational, observational study in type 2 diabetes: baseline characteristics from eight national cohorts. Int J Clin Pract 2008 62 : 1809 19.
14. Bebakar WM, Chow CC, Kadir KA et al., BIAsp-3021 study group. Adding biphasic insulin aspart 30 once or twice daily is more efficacious than optimizing oral antidiabetic treatment in patients with type 2 diabetes. Diabetes Obes Metab 2007 9 : 724 32.
15. Luzio S, Dunseath G, Peter R et al. Comparison of the pharmacokinetics and pharmacodynamics of biphasic insulin aspart and insulin glargine in people with type 2 diabetes. Diabetologia 2006 49 : 1163 8.
16. Weyer C, Heise T, Heinemann L. Insulin aspart in a 30/70 premixed formulation. Pharmacodynamic properties of a rapid-acting insulin analog in stable mixture. Diabetes Care 1997 20 : 1612 4.
17. Jacobsen LV, Søgaard B, Riis A. Pharmacokinetics and pharmacodynamics of a premixed formulation of soluble and protamine-retarded insulin aspart. Eur J Clin Pharmacol 2000 56 : 399 403.
18. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998 352 : 837 53.
19. Heise T, Eckers U, Kanc K et al. The pharmacokinetic and pharmacodynamic properties of different formulations of biphasic insulin aspart: a randomized, glucose clamp, crossover study. Diabetes Technol Ther 2008 10 : 479 85.
20. Khutsoane D, Sharma SK, Almustafa M, Jang HC et al., PRESENT Study Group. Biphasic insulin aspart 30 treatment improves glycaemic control in patients with type 2 diabetes in a clinical practice setting: experience from the PRESENT study. Diabetes Obes Metab 2008 10 : 212 22.
21. Holman RR, Thorne KI, Farmer AJ et al., 4-T Study Group. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007 357 : 1716 30.
22. Hirao K, Arai K, Yamauchi M et al. for the Japan Diabetes Clinical Data Management Study Group. Six-month multicentric, open-label, randomized trial of twice-daily injections of biphasic insulin aspart 30 versus multiple daily injections of insulin aspart in Japanese type 2 diabetic patients (JDDM 11). Diab Res Clin Pract 2008 79 : 171 6.